01—Abstract
Summary
Summary of the 8-K filed November 19, 2024. Cited figures are marked; the original filing is the authoritative source.
On November 19, 2024, BeiGene, Ltd. (NASDAQ: BGNE, now operating as BeOne Medicines and listed as ONC) disclosed under Item 8.01 that its U.S. subsidiaries settled patent litigation with MSN Pharmaceuticals and MSN Laboratories on November 14, 2024.
MSN had filed an Abbreviated New Drug Application (ANDA) seeking to market a generic version of BRUKINSA (zanubrutinib) and challenged several Orange Book patents. The settlement grants MSN the right to sell a generic BRUKINSA in the United States no earlier than June 15, 2037, subject to customary acceleration or extension provisions. The composition-of-matter patent, which expires in April 2034, was not challenged in the litigation, so it is not directly affected by the settlement terms as described.
The settlement, together with the previously dismissed Sandoz litigation, resolves all patent suits BeiGene brought against companies that filed ANDAs for generic BRUKINSA. For investors, this provides a defined exclusivity runway in the U.S. that extends well beyond the composition-of-matter patent expiry, reducing near-term generic entry risk and supporting long-term revenue visibility for BRUKINSA. The agreement must still be submitted to the U.S. Federal Trade Commission and the Department of Justice, and the parties have filed a joint stipulation to dismiss the MSN suit.
The filing contains no quantitative financial data, guidance, or disclosure of settlement payments or royalty terms. Investors should note that the filing is a brief disclosure and that the full Settlement Agreement, along with any regulatory review outcome, will determine the complete economic impact.
02—Key points
Key Highlights
- Settlement agreement with MSN Pharmaceuticals and MSN Laboratories was entered into on November 14, 2024, resolving patent litigation over BRUKINSA (zanubrutinib).
- MSN may sell a generic BRUKINSA in the U.S. no earlier than June 15, 2037, subject to potential acceleration or extension under customary settlement terms.
- The composition-of-matter patent for BRUKINSA, expiring April 2034, was not challenged by MSN in the litigation.
- The MSN settlement and earlier dismissal of the Sandoz litigation resolve all BeiGene patent suits against ANDA filers seeking generic BRUKINSA.
- Parties filed a joint stipulation to dismiss the MSN suit; the settlement must be submitted to the FTC and DOJ under U.S. law.
- The filing discloses no financial terms, royalty or payment details, or revenue impact estimates.
- The filing is a brief Item 8.01 (Other Events) disclosure with an Inline XBRL cover page exhibit only.
03—Questions
Frequently Asked Questions
When could generic versions of BRUKINSA enter the U.S. market?
Under the MSN settlement, generic entry is permitted no earlier than June 15, 2037, subject to potential acceleration or extension under customary settlement provisions. The filing does not specify the exact conditions for acceleration or extension.
Does this settlement change the composition-of-matter patent protection?
No. The composition-of-matter patent, expiring in April 2034, was not challenged by MSN in the litigation. The settlement addresses the other Orange Book patents that MSN challenged.
Does this resolve all generic challenges to BRUKINSA?
According to the filing, the MSN settlement and the previously dismissed Sandoz litigation resolve all patent litigation BeiGene brought against companies that filed ANDAs for generic BRUKINSA. The filing does not address generic challenges outside of that litigation.
Is the settlement final, and what regulatory steps remain?
The parties have filed a joint stipulation to dismiss the suit with the court. The Settlement Agreement must still be submitted to the U.S. Federal Trade Commission and the U.S. Department of Justice, as required by law for settlements of this type.
What is the financial impact of the settlement on BeiGene?
The filing does not disclose any financial terms, such as payments, royalties, or revenue projections. Investors should review future company disclosures, such as quarterly reports, for any quantified impact.
04—Continue